Heartflow sues Cleerly over patent infringement allegations

Heartflow has filed a suit against Cleerly, alleging that 3 of the Texas-based company’s artificial quality (AI)-based tools for coronary artery illness (CAD) valuation infringe connected six of its patents.

Filed connected 13 April successful the US District Court for the Eastern District of Texas, Heartflow’s ailment seeks “permanent injunctive alleviation and damages” arising from what the institution claims is Cleerly’s “unauthorised and continued use” of Heartflow’s patented technology.

Heartflow states that its suit has arisen from “one of the astir egregious examples of piracy” successful the aesculapian exertion industry, putting Cleerly CEO Dr James Min successful the lawsuit’s crosshairs. Min served arsenic a advisor to Heartflow from 2012 to 2017.

Outlining the lawsuit’s rationale, Heartflow said it is seeking to support the “extraordinary investment” that led to its instauration of “the world’s archetypal AI-powered, non-invasive cardiac diagnostic platform”.

The 3 technologies successful the scope of Heartflow’s suit are Cleerly’s Ischemia, Plaque Analysis, and Compare products. These AI-based products are utilized to find inadequate humor proviso (ischaemia), the grade of coronary plaque buildup (atherosclerosis) successful the coronary arteries, and to supply longitudinal illness valuation truthful clinicians tin measure changes successful CAD progression, respectively.

The cardinal allegation wrong Heartflow’s suit is that the trio of Cleerly products infringe connected patents “with precedence dates from 2012 to 2018”.

Heartflow CEO John Farquhar commented: "We instrumentality earnestly our work to support the intelligence spot that supports this tract and the clinicians and patients it serves."

The suit alleges that without informing his colleagues astatine Heartflow, Min launched a competing endeavor “built upon Heartflow’s pioneering innovations” aft gaining entree to Heartflow’s technology, commercialized secrets, and confidential concern information.

Cleerly has refuted Heartflow’s allegations. In written comments provided to Medical Device Network, Min stated that Cleerly is “confident” successful its “extensive and well-established intelligence spot portfolio” and the “originality” of its technology.

Min continued: “Cleerly has published landmark objective subject that has redefined however cardiovascular illness is understood and treated, which has formed the ground of our caller technologies that supply physicians with actionable insights into their patients’ bosom health.”

"Heartflow sues Cleerly implicit patent infringement allegations" was primitively created and published by Medical Device Network, a GlobalData owned brand.